Loading...
WELCOME 2017-11-20T20:36:25+00:00

Patient No. 1 and the cancer trial here that just might change everything

August 8th, 2018|0 Comments

Cincinnati Enquirer (Aug. 8, 2018) If you saw Bob Rulli on the street, you’d never guess he had cancer. He's the first person to receive a first-of-its-kind drug made in Cincinnati. (Photo: Kareem Elgazzar/The Enquirer) [...]

Bexion Pharmaceuticals, Inc. Announces Grant from CancerFree KIDS

June 19th, 2018|0 Comments

CancerFree KIDS Awards Nationwide Children’s Hospital Monies to Initiate Pediatric Trial FOR IMMEDIATE RELEASE Covington, KY, June 19, 2018 - Sometimes things come full circle. Fourteen years ago , CancerFree KIDS awarded its very first [...]

Bexion Pharmaceuticals, Inc. Announces Data at 2018 ASCO Annual Meeting from Ongoing Phase I BXQ-350 Clinical Trial

June 12th, 2018|0 Comments

FOR IMMEDIATE RELEASE Covington, KY ~ June 12, 2018 - Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, discussed data from 17 patients enrolled in the Phase Ia portion of [...]

Bexion Pharmaceuticals is developing innovative cures for cancer.

Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.

Read More About Bexion
Clinical Trials

Clinical Trials

In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).

Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857